Gilead Sciences (GILD) Tops Q3 EPS by 32c; offers guidance

Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.47, $0.32 better than the analyst estimate of $2.15. Revenue for the quarter came in at $7.8 billion versus the consensus estimate of $7.45 billion.

GUIDANCE:

Gilead Sciences sees FY2025 EPS of $8.05-$8.25, versus the consensus of $8.05. Gilead Sciences sees FY2025 Product revenue of $28.4-28.7 billion, versus the consensus of $28.836 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• Grocery Outlet Holding (GO) PT Raised to $11.50 at UBS
• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c